GE HealthCare Technologies walked into this report with the stock up over the past month and quarter, then gave back 2.7% today to close near US$69.94. That looks more like an emotional reaction than a verdict on collapse. Q2 brought solid imaging and diagnostics momentum, with revenue at US$5.3b and basic earnings per share of US$1.24. The real story is a squeeze on profitability, as trailing net profit margin has moved down to 9.3%. Today’s selling is the market voting on that margin pressure in real time.

Is GE HealthCare Technologies now a clear bargain on 15.9x P/E, or is the lower margin profile a warning that the stock deserves this discount? Compare the current share price against our valuation analysis for GE HealthCare…